» Download Public Reports
About 16 000 reports
- Company report
- May 2013
- 5 pages
- by Corporation
... Involved, even indirectly, with an important therapeutic area that addresses the needs of millions of patients who suffer from respiratory disease is particularly meaningful to all of us at elan." Relvar ...
May 2013
... Of imugene platform linguet Is a proprietary drug delivery technology that improves the efficacy and safety of a diverse number of prescription and over the counter medicines. The platform technology ...
May 2013
... On applying gene therapy technology to genetically modify a patient S own t-cells, known as chimeric antigen receptor (car) t-cells, to target and destroy cancer cells. Celgene has an option to license any ...
May 2013
... Stribild gilead hiv-1 infection aug. 27 Neutroval sicor biotech neutropenia aug. 29 Linzess forest ibs aug. 30 Xtandi astellas prostate cancer aug. 31 Bosulif pfizer leukemia sep. 4 Aubagio sanofi multiple ...
May 2013
... Uncertainty was positively correlated to five poms-sf subscales, anger, confusion, depression, fatigue, and tension (all with p ...
May 2013
... To production interruptions and diminished capacity Economic choices are made where older, less profitable drugs are eliminated as new generics come to market By year-end 2012, we will see $34b in new ...
May 2013
... Sorbentstm competition 38 no approved therapies in the eu or us to prevent or treat organ failure Sepsis Ards and ali Burn injury Trauma Severe acute pancreatitis Cardiopulmonary bypass ...
May 2013
... We know patients are deficient in it, so important to treat it anyway. Also why not have nonunion patients take a product that has: Calcium (dairy) vitamin k2 (natto, fermented cheese and organ ...
» Purchase Premium Reports
(From $ 99 - $ 6 995)
About 6 400 reports
- $ 6 995
- Industry report
- February 2013
- by Global Data
PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis ...
February 2013
$ 6 995
Protelos (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Protelos (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Forteo (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Forteo (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Reclast (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Reclast (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Odanacatib (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Odanacatib (Osteoporosis) - Forecast and Market Analysis ...
February 2013
$ 6 995
BA-058 (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?BA-058 (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Evista (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Evista (Osteoporosis) - Forecast and Market Analysis to 2022?. ...